Novel therapies targeting IL‐5 signaling are approved for the treatment of eosinophilic asthma,12, 13 and anti‐IL‐5 and anti‐Siglec‐8 therapies are currently in development for the treatment of diverse eosinophilic diseases.14, 15, 16. This evidence concerns the gene IL5 and eosinophil disorder.